Prof. Arndt Hartmann

Pathological Institute

Research projects

  • Pathology and Molecular Pathology with research focus on bladder cancer, renal cell carcinoma, head and neck and breast cancer.
  • Prognostic and predictive molecular tumour markers.
  • Digital pathology and devolopment of AI prediction models for diagnosis, molecular changes and therapy prediction.
  • Characterization of the immunological tumor microenvironment and correlation to response to immunooncological therapy.

Current projects

  • D039: EMT specific splicing mediates ferroptosis sensitivity

    (FAU Funds)

    Term: 1. July 2023 - 31. December 2025
    We have demonstrated that the EMT-activator ZEB1 provides cancer cells not only with aberrant motility, but also with survival traits enabling tumor progression, metastasis and drug resistance. Our aim is to eliminate these aggressive ‘untargetable’ EMT-state cancer cells, which strikingly show a high sensitivity to ferroptotic cell death. In this project, we want to elucidate the molecular basis of ZEB1 – associated ferroptosis sensitivity to exploit it as a novel therapeutic target.
  • J101: AI-based support for histopathology evaluation of autoinflammatory and malignant GI diseases

    (FAU Funds)

    Term: 1. January 2023 - 30. June 2025
    The proposed projects aims at using methods from AI-based image analysis to evaluate histopathologic samples from the field of gastrointestinal pathology. Specifically, samples from patients with inflammatory bowel diseases and malignancies of the colorectum will be evaluated. It is the aim of the project to develop algorithms that quantify and detect specific morphologic properties of these samples and integrate them with other data modalities.
  • Integratives Konzept zur personalisierten Präzisionsmedizin in Prävention, Früh-Erkennung, Therapie und Rückfallvermeidung am Beispiel von Brustkrebs

    (Third Party Funds Single)

    Term: 1. October 2020 - 30. September 2024
    Funding source: Bayerisches Staatsministerium für Gesundheit und Pflege, StMGP (seit 2018)

    Breast cancer is one of the leading causes of death in the field of oncology in Germany. For the successful care and treatment of patients with breast cancer, a high level of information for those affected is essential in order to achieve a high level of compliance with the established structures and therapies. On the one hand, the digitalisation of medicine offers the opportunity to develop new technologies that increase the efficiency of medical care. On the other hand, it can also strengthen patient compliance by improving information and patient integration through electronic health applications. Thus, a reduction in mortality and an improvement in quality of life can be achieved. Within the framework of this project, digital health programmes are going to be created that support and complement health care. The project aims to provide better and faster access to new diagnostic and therapeutic procedures in mainstream oncology care, to implement eHealth models for more efficient and effective cancer care, and to improve capacity for patients in oncologcal therapy in times of crisis (such as the SARS-CoV-2 pandemic). The Chair of Health Management is conducting the health economic evaluation and analysing the extent to which digitalisation can contribute to a reduction in the costs of treatment and care as well as to an improvement in the quality of life of breast cancer patients.

Recent publications






Related Research Fields